IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN HIMS & HERS HEALTH, INC. (HIMS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE AUGUST 25, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Our writer reveals what he thinks is the most exciting from the four investments he made in his Stocks and Shares ISA last ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, ...

Investing.com -- AI-related stocks topped trading activity on Robinhood U.K. in June, led by Nvidia (NASDAQ: NVDA ), ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Hims & Hers' high valuation is no longer justified amid mounting execution and revenue risks. Click here to read why I ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Hims & Hers Health and Novo Nordisk announced a partnership a few months ago, and it has already come to an end. Novo Nordisk ...

你是否听说过诺和诺德与Hims&Hers的短暂合作？这场仅维持58天的商业联姻戛然而止，引发了市场的广泛关注。诺和诺德的愤怒声明不仅揭示了减肥药市场的复杂局势，也折射出全球制药行业面临的生存危机。